The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial
Open accessAbstract
BACKGROUND.: Few randomized trials have compared the survival benefit of interferon‐alfa over controls in metastatic renal cell carcinoma, and none has been performed using interleukin‐2. The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments. METHODS.: Patients were randomized in a 2‐by‐2 factorial design to medroxyprogesterone acetate 200 mg daily, interferon‐alfa 9 million IU 3 times a week, subcutaneous interleukin‐2 9 million IU daily, or a combination of both cytokines. Tumor response was evaluated at Week 12 and Month 6; progression‐free patients received further identical treatment for a maximum of 3 additional months. Primary endpoint was overall survival; secondary endpoints were disease‐free survival, response rate, toxicity, and quality of life. Survival was analyzed on an intent‐to‐treat basis. RESULTS.: From January 2000 to July 2004, 492 patients were enrolled. Analysis was performed after a 29.2‐month median follow‐up (range, 0 months to 54.6 months). There were no significant survival differences between the 244 interferon‐alfa‐treated patients and 248 noninterferon‐alfa patients (hazard ratio, 1.00; 95% CI, 0.81–1.24) or between the 247 interleukin‐2 and 245 noninterleukin‐2‐treated patients (hazard ratio, 1.07; 95% CI, 0.87–1.33; log rank, 0.99 and 0.52, respectively). Grade 3–4 toxicities were significantly more frequent in cytokine‐treated patients than in medroxyprogesterone‐treated patients. CONCLUSIONS.: Subcutaneous interleukin‐2 and/or interferon‐alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity. Newly available angiogenesis inhibitors should be preferred for these patients. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Cited by
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Self-citationGucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Escudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citation
Metadata
- Authors
- Negrier, S., Perol, D., Ravaud, A., Chevreau, C., Bay, J., Delva, R., Sevin, E., Caty, A., & Escudier, B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-10-11
- Volume
- 110
- Issue
- 11
- Pages
- 2448-2457
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1978670159
- Cited by
- 184
- References
- 3
- FWCI
- 21.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.